Legal
← Earnings Calls
01
02
03
04 05 06
Tone
AI
A1 A2 A3 A4 A5
PFE
FY2026 Q1
Improving
Pfizer, Inc. earnings call
Buzzberg read
Vindamax settlements push post-2028 growth visibility to high single-digit CAGR
Pfizer reported strong Q1 2026 results with revenues exceeding expectations. Management reiterated FY2026 guidance and highlighted a robust pipeline, particularly in obesity and oncology, plus legal wins improving the post-2028 growth outlook. Q1 revenues reached $14.5 billion, a 2% operational increase; adjusted EPS was $0.75, exceeding expectations.
Buzzberg read Vindamax settlements push post-2028 growth visibility to high single-digit CAGR Pfizer reported strong Q1 2026 results with revenues exceeding expectations. Management reiterated FY2026 guidance and highlighted a robust pipeline, particularly in obesity and oncology, plus legal wins improving the post-2028 growth outlook. Q1 revenues reached $14.5 billion, a 2% operational increase; adjusted EPS was $0.75, exceeding expectations. Read full analysisCollapse analysis
Pfizer reported strong Q1 2026 results with revenues exceeding expectations. Management reiterated FY2026 guidance and highlighted a robust pipeline, particularly in obesity and oncology, plus legal wins improving the post-2028 growth outlook. Q1 revenues reached $14.5 billion, a 2% operational increase; adjusted EPS was $0.75, exceeding expectations.
- FY2026 guidance maintained: revenue of $59.5-62.5 billion and adjusted EPS of $2.80-3.00.
- Legal settlements on Vindamax and Comirnaty contracts improve post-2028 cash flow and support dividend.
- Obesity program (Medcera) advancing with 10 phase 3 studies planned; first approval targeted in 2028.
Revenue$14.451B-18% QoQ
EPS$0.75+14% QoQ
Gross margin67.26%Reported
Operating margin27.9%Reported
6 grounded callouts
What matters now
The highest-signal changes from the call.
Obesity
Pfizer targets 2028 first approval for monthly obesity portfolio with 10 phase 3 starts
Vaccines
Adult vaccine strategy leapfrogs to 35-serotype fifth-generation candidate
Show 3 more callouts
Legal
Belgian court ruling on Comirnaty supports future EPS and cash flow
Guidance
Q1 strength was enough to consider raising guidance, but held on COVID seasonality
Commercial
Launched and acquired products grew 22% operationally in Q1
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| Revenue | $14.451B | -18% QoQ |
| EPS | $0.75 | +14% QoQ |
| Gross margin | 67.26% | Reported |
| Operating margin | 27.9% | Reported |
| Free cash flow | $2.179B | -52% QoQ |
| Capex | $0.436B | Reported |
Forward-looking
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| EPS | FY2026 | $2.80–$3.00 | $2.90 | Maintained |
| Gross margin | FY2026 | 75% | 75% | Guided |
| Revenue | FY2026 | $59.5B–$62.5B | $61B | Maintained |
| Revenue | FY2029 | 7%–9% | 8% | Initiated |
AI, capex & demand read
Management read
Confident
Management emphasized a strong start, repeated 'disciplined execution,' reaffirmed full-year guidance, and projected increased visibility into post-2028 growth and cash flow, grounding an upbeat outlook.
Management AI read
Management said AI is a key strategic priority embedded across R&D, commercial, manufacturing, and core enterprise functions. They are pairing frontier AI tools with training to compress discovery and development timelines and unlock insights from Pfizer's vast translational and clinical data.
all 7 named companies below
Companiesreturns since call
Partners
Partners
Dave Denton
Pfizer's gross margin commentary confirms ongoing 50-50 profit share with BioNTech for Comirnaty, underscoring alignment of interests and shared financial exposure.
Evidence
“Comirnaty, which has a 50-50 profit split with our partner, BioNTech.”
Partners
Dr. Albert Bourla
Pfizer highlights its licensing agreement with Bayer as a strategic asset supporting its R&D pipeline and future growth, indicating deepening partnership.
Evidence
“opportunities we have added through strategic moves, such as our acquisition of Metcera and our licensing agreements with 3S Bayer and Yalthal.”
Competitors
Competitors
Chris Bosso
Pfizer's PD-1/VEGF bispecific (4404) competes with Roche's bevacizumab-based therapies, claiming higher VEGFA affinity.
Evidence
“as well as high affinity affinity than what's seen with bevacizumab or that's seen with um competitive and vgfpd1 molecules.”
Competitors
Amir (Head of U.S. Vaccines)
Pfizer will advance directly to a fifth-generation adult pneumococcal vaccine candidate covering 35 serotypes, aiming to maintain leadership in the adult market. — This next-gen vaccine targets broader serotype coverage, strengthening Pfizer's competitive position against Merck's adult pneumococcal vaccine.
Evidence
“Prevnar Adult, even after many months of competition from Mark, holding share steady at 70%.”
Competitors
Alexander (Head of International Contracts & Market Access)
Pfizer's PD-1/VEGF bispecific (4404) shows differentiated early data with high VEGFA affinity, potentially strengthening its lung cancer portfolio. — This could impact the competitive landscape in non-small cell lung cancer, challenging existing PD-1/angiogenesis combo therapies.
Evidence
“Lilly really introduced their asset in the beginning of last year. So it's not like we're coming many years after the introduction of those assets.”
Investees
Investees
Dr. Albert Bourla
Pfizer's Seagen acquisition is delivering strong oncology revenue growth, validating strategic investment in ADCs.
Evidence
“The 20% year-over-year operational revenue growth in the quarter of our seeds and products shows that we have made good progress in deepening our presence within the oncology community.”
Supply chain
Supply chain
Dr. Albert Bourla
Pfizer's obesity program (Medcera) is advancing rapidly, with 10 phase three studies planned this year and a target first approval in 2028. — This signals a major push into the obesity market, intensifying competition with Lilly and Novo Nordisk.
Evidence
“We intend to advance 10 phase three studies this year, and we are targeting a first approval in 2028 from a portfolio that includes ultra-long-acting peptides.”
External signals
Supply-chain alpha · 5returns since call
Pfizer's Vindamax patent settlement extends exclusivity, significantly improving post-2028 revenue CAGR to high single digits.
Pfizer will advance directly to a fifth-generation adult pneumococcal vaccine candidate covering 35 serotypes, aiming to maintain leadership in the adult market.
Pfizer's obesity program (Medcera) is advancing rapidly, with 10 phase three studies planned this year and a target first approval in 2028.
Pfizer's PD-1/VEGF bispecific (4404) shows differentiated early data with high VEGFA affinity, potentially strengthening its lung cancer portfolio.
Pfizer's robust BD capacity of ~$7 billion combined with successful legal settlements could enable further strategic acquisitions or share buybacks.
Methodology & coverage
Management-only analysis. All 7 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.